I agree that this site is using cookies. You can find further informations here.
X
Casadei Gardini, A.
580  results:
Search for persons X
?
1

287P Association of progression-free survival (PFS) with ov..:

Castet, F. ; Fabregat-Franco, C. ; Kim, J.W....
Annals of Oncology.  35 (2024)  - p. S121 , 2024
Link: https://doi.org/10.1016/..
 
?
2

292P Extended molecular profiling (EMP) and access to targe..:

Genovesi, V. ; Rimini, M. ; Pressiani, T....
Annals of Oncology.  35 (2024)  - p. S123 , 2024
Link: https://doi.org/10.1016/..
 
?
3

65P Atezolizumab plus bevacizumab versus lenvatinib for unr..:

Rimini, M. ; Casadei Gardini, A. ; Persano, M....
Immuno-Oncology and Technology.  16 (2022)  - p. 100170 , 2022
Link: https://doi.org/10.1016/..
 
?
4

111P Identification of atezolizumab plus bevacizumab progno..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100215 , 2022
Link: https://doi.org/10.1016/..
 
?
5

108P Role of the prognostic nutritional index in predicting..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100212 , 2022
Link: https://doi.org/10.1016/..
 
?
6

67P Real-world data for atezolizumab plus bevacizumab in un..:

Persano, M. ; Rimini, M. ; Tada, T....
Immuno-Oncology and Technology.  16 (2022)  - p. 100172 , 2022
Link: https://doi.org/10.1016/..
 
?
7

78P Clinical outcomes with atezolizumab plus bevacizumab (A..:

Persano, M. ; Rimini, M. ; Cascinu, S...
Immuno-Oncology and Technology.  16 (2022)  - p. 100182 , 2022
Link: https://doi.org/10.1016/..
 
?
8

PO-1214 Toxicity profile of adjuvant hypofractionated Image..:

SLIM, N. ; Pacifico, P. ; Passoni, P....
Radiotherapy and Oncology.  161 (2021)  - p. S1005-S1006 , 2021
Link: https://doi.org/10.1016/..
 
?
9

PO-1212 Outcome of adjuvant hypofractionated radiotherapy c..:

Slim, N. ; Pacifico, P. ; Passoni, P....
Radiotherapy and Oncology.  161 (2021)  - p. S1004-S1005 , 2021
Link: https://doi.org/10.1016/..
 
?
10

EP-1487: The prognostic role of haemoglobin in patients und..:

Martini, S. ; Iorio, G.C. ; Franco, P....
Radiotherapy and Oncology.  127 (2018)  - p. S806-S807 , 2018
Link: https://doi.org/10.1016/..
 
?
11

EP-1461: Immune inflammation indicators in anal cancer pati..:

Franco, P. ; Montagnani, F. ; Arcadipane, F....
Radiotherapy and Oncology.  127 (2018)  - p. S793-S794 , 2018
Link: https://doi.org/10.1016/..
 
?
12

Treatment of squamous cell carcinoma of the anal canal: A n..:

Casadei Gardini, A. ; Passardi, A. ; Fornaro, L....
Critical Reviews in Oncology/Hematology.  123 (2018)  - p. 52-56 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Immune Inflammation Indicators Predict Outcome in Anal Canc..:

Franco, P. ; Montagnani, F. ; Arcadipane, F....
International Journal of Radiation Oncology*Biology*Physics.  102 (2018)  3 - p. e5-e6 , 2018
Link: https://doi.org/10.1016/..
 
?
14

Validation of a simple scoring system to predict sorafenib ..:

Tortora, R. ; Casadei Gardini, A. ; Cordone, G....
Digestive and Liver Disease.  49 (2017)  1 - p. e42 , 2017
Link: https://doi.org/10.1016/..
 
?
15

Ang-2 polymorphisms in relation to outcome in advanced HCC ..:

Marisi, G. ; Scartozzi, M. ; Faloppi, L....
Digestive and Liver Disease.  49 (2017)  1 - p. e19 , 2017
Link: https://doi.org/10.1016/..
 
1-15